JPRN-jRCT1070220091
Recruiting
未知
Follow-up study of the long-term efficacy and safety of investigator-initiated clinical trials (HUCV002-01-02 study and HUCV002-01-03 study) of intravenous HUCV002-01 in patients with chronic heart failure.
Ide Tomomi0 sites30 target enrollmentJanuary 18, 2023
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Ide Tomomi
- Enrollment
- 30
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\)Patients who voluntarily participated in the preceding investigator\-initiated clinical trial (protocol number: Study HUCV002\-01\-02 or Study HUCV002\-01\-03\) and were administered the investigational product.
- •2\)Patients who has ability to understand and sign the informed consent
Exclusion Criteria
- •1\) Patients whom the PI or investigators decided as inappropriate for the study.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
A follow-on study in patients who have received gene therapy for Beta-thalassemia in the TIGET-BTHAL study to assess safety and effectiveness of treatment.Beta-thalassemiaMedDRA version: 20.1Level: LLTClassification code 10054660Term: Thalassemia betaSystem Organ Class: 100000004850Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]EUCTR2017-001366-14-ITGLAXOSMITHKLINE RESEARCH AND DEVELOPMENT10
Active, not recruiting
Phase 1
An open-label extension (OLE) study to evaluate the long-term safety and efficacy of ralinepag in patients with pulmonary arterial hypertensioPulmonary arterial hypertension (PAH)MedDRA version: 20.0Level: LLTClassification code 10077731Term: Pulmonary hypertension WHO functional class ISystem Organ Class: 100000004855Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2018-001189-40-PLnited Therapeutics Corporation1,000
Active, not recruiting
Phase 1
An open-label extension (OLE) study to evaluate the long-term safety and efficacy of ralinepag in patients with pulmonary arterial hypertensioPulmonary arterial hypertension (PAH)MedDRA version: 20.0Level: LLTClassification code 10077731Term: Pulmonary hypertension WHO functional class ISystem Organ Class: 100000004855Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2018-001189-40-NLnited Therapeutics Corporation1,000
Recruiting
Phase 1
An open-label extension (OLE) study to evaluate the long-term safety and efficacy of ralinepag in patients with pulmonary arterial hypertensioPulmonary arterial hypertension (PAH)MedDRA version: 20.0Level: LLTClassification code: 10077731Term: Pulmonary hypertension WHO functional class I Class: 10038738Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]CTIS2023-509305-68-00nited Therapeutics Corp.633
Active, not recruiting
Phase 1
An open-label extension (OLE) study to evaluate the long-term safety and efficacy of ralinepag in patients with pulmonary arterial hypertensioEUCTR2018-001189-40-BEnited Therapeutics Corporation1,000